July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...
Recent research from the University of Helsinki sheds new light on the behavior of the KRAS gene in two of the deadliest cancers—pancreatic and colorectal cancer. These findings suggest potential ...
A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene ...
Responsible for nearly 10 million deaths worldwide in 2020, cancer consistently ranks among the leading causes of death each year. Brought on by genetic mutations and external risk factors, cancer is ...
Researchers at MUSC Hollings Cancer Center have discovered why a powerful cancer-causing gene mutation rarely appears in pancreatic tumors. The study, published in Cancer Research Communications, ...
In an early trial, a one-size-fits-all vaccine showed promise in preventing hard-to-treat pancreatic cancers from coming back. Pancreatic cancer is of particular concern. The five-year survival rate ...
Choosing among cancer treatments increasingly involves determining whether tumor cells harbor specific, mutated "oncogenes" that drive abnormal growth and that may also be especially vulnerable or ...
The KRAS gene is responsible for producing a protein also called KRAS that’s involved in regulating the entrance of signaling molecules into the nucleus of a cell. Many of the nuclear signaling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results